Skip to content

Study · Animal study (in vivo) · mouse · 2014

7 results

Protective role of humanin on bortezomib-induced bone growth impairment in anticancer treatment.

Eriksson E, Wickström M, Perup LS, Johnsen JI, Eksborg S, Kogner P, Sävendahl L

Journal of the National Cancer Institute1 Mar 2014Cited by 37 (Europe PMC)

PMID24586107 (opens in a new tab)DOI10.1093/jnci/djt459 (opens in a new tab)PepBankPUB-24586107
Source linkPubMedAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

6 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In mice, adding HNG to bortezomib significantly prevented the bortezomib-induced impairment of linear bone growth, compared with bortezomib alone.

    In plain wordsIn mice, adding HNG to bortezomib largely prevented the bone growth slowdown that bortezomib caused alone.

    Peptide
    Humanin
    Outcome
    IncreaseLinear bone growth rate, HNG plus bortezomib versus bortezomib
    Study

    mousen: not reported in source

    mice with human neuroblastoma or medulloblastoma xenografts
    Comparator
    Bortezomib alone
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    1 µg/mouse · one 2-week cycle (2 injections/week)As given in this study (mouse).

    Measurements

    Linear bone growth
    0.15 mm/day
    HNG plus bortezomib

    Source sentences

    Summary
    an effect significantly prevented by the addition of HNG (0.15 mm growth/day, 95% CI = 0.14 to 0.16 mm/day; P < .001 vs bortezomib only; P = 0.03 vs vehicle).
    1 context sentence
    Summary · context
    Mice with human neuroblastoma or medulloblastoma tumor xenografts (9-13 animals/group) received one 2-week cycle (2 injections/week) of bortezomib (0.8 mg/kg or 1.0mg/kg), or HNG (1 µg/mouse), or the combination of HNG/bortezomib, or vehicle.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In mice with human tumor xenografts, HNG did not interfere with the tumor growth delay caused by bortezomib.

    In plain wordsIn mice with human tumors, HNG did not reduce the tumor-slowing effect of bortezomib.

    Peptide
    Humanin
    Outcome
    No significant changeAnticancer effect of bortezomib in human tumor xenografts
    Study

    mousen: not reported in source

    mice with human neuroblastoma or medulloblastoma xenografts
    Comparator
    Bortezomib alone
    Outcome group
    Tumor growth · Cancer
    Studied dose
    1 µg/mouse · one 2-week cycle (2 injections/week)As given in this study (mouse).

    Source sentences

    Summary
    Bortezomib delayed tumor growth, and HNG did not interfere with the anticancer effect when studied in human tumor xenografts or cell lines.
    1 context sentence
    Summary · context
    Mice with human neuroblastoma or medulloblastoma tumor xenografts (9-13 animals/group) received one 2-week cycle (2 injections/week) of bortezomib (0.8 mg/kg or 1.0mg/kg), or HNG (1 µg/mouse), or the combination of HNG/bortezomib, or vehicle.
  3. 03LabEx vivo tissueEfficacy outcome

    In cultured human growth plate cartilage, combining bortezomib with HNG entirely prevented the apoptosis that bortezomib induced.

    In plain wordsIn lab-grown human growth plate cartilage, HNG fully prevented the cell death that bortezomib caused.

    Peptide
    Humanin
    Outcome
    DecreaseBortezomib-induced apoptosis in human growth plate cartilage
    Study

    humann: not reported in source

    cultures of human growth plate cartilage
    Comparator
    Bortezomib alone
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    However, when combining with HNG, bortezomib-induced apoptosis was entirely prevented, as was Bax and PARP activation.
    1 context sentence
    Summary · context
    Bortezomib was highly toxic when added to cultures of human growth plate cartilage, with markedly increased apoptosis compared with control (P < .001).
  4. 04LabEx vivo tissueMechanism

    In cultured human growth plate cartilage, combining bortezomib with HNG prevented the Bax activation that bortezomib induced.

    In plain wordsIn lab-grown human growth plate cartilage, HNG prevented a cell-death protein, Bax, from being switched on by bortezomib.

    Peptide
    Humanin
    Outcome
    DecreaseBortezomib-induced Bax activation in human growth plate cartilage
    Study

    humann: not reported in source

    cultures of human growth plate cartilage
    Comparator
    Bortezomib alone
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    However, when combining with HNG, bortezomib-induced apoptosis was entirely prevented, as was Bax and PARP activation.
    1 context sentence
    Summary · context
    Cultures of human growth plate cartilage, chondrogenic- and cancer cell lines, and immunohistochemistry for detection of proapoptotic proteins were also used.
  5. 05LabEx vivo tissueMechanism

    In cultured human growth plate cartilage, combining bortezomib with HNG prevented the PARP activation that bortezomib induced.

    In plain wordsIn lab-grown human growth plate cartilage, HNG prevented a cell-death protein, PARP, from being switched on by bortezomib.

    Peptide
    Humanin
    Outcome
    DecreaseBortezomib-induced PARP activation in human growth plate cartilage
    Study

    humann: not reported in source

    cultures of human growth plate cartilage
    Comparator
    Bortezomib alone
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    However, when combining with HNG, bortezomib-induced apoptosis was entirely prevented, as was Bax and PARP activation.
    1 context sentence
    Summary · context
    Cultures of human growth plate cartilage, chondrogenic- and cancer cell lines, and immunohistochemistry for detection of proapoptotic proteins were also used.
  6. 06LabIn vitro (cells)Efficacy outcome

    In human cancer cell lines, HNG did not interfere with the anticancer effect of bortezomib.

    In plain wordsIn human cancer cells grown in the lab, HNG did not reduce the effect of bortezomib.

    Peptide
    Humanin
    Outcome
    No significant changeAnticancer effect of bortezomib in human cell lines
    Study

    humann: not reported in source

    human cancer cell lines
    Comparator
    Bortezomib alone
    Outcome group
    Tumor growth · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Bortezomib delayed tumor growth, and HNG did not interfere with the anticancer effect when studied in human tumor xenografts or cell lines.
    1 context sentence
    Summary · context
    Cultures of human growth plate cartilage, chondrogenic- and cancer cell lines, and immunohistochemistry for detection of proapoptotic proteins were also used.

Studies that did not test the peptide alone1

In this study, Humanin was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Humanin.

  1. 07AnimalNot a test of Humanin aloneAnimal study (in vivo)Efficacy outcome

    In mice, linear bone growth with HNG plus bortezomib (0.15 mm/day) remained lower than with vehicle (0.19 mm/day).

    In plain wordsIn mice, bone growth with HNG plus bortezomib was still lower than with vehicle.

    Peptide
    Humanin
    Outcome
    DecreaseLinear bone growth rate, HNG plus bortezomib versus vehicle
    Study

    mousen: not reported in source

    mice with human neuroblastoma or medulloblastoma xenografts
    Comparator
    Vehicle
    Outcome group
    Bone and joint · Musculoskeletal

    Measurements

    Linear bone growth
    0.15 mm/day
    HNG plus bortezomib

    Source sentences

    Summary
    an effect significantly prevented by the addition of HNG (0.15 mm growth/day, 95% CI = 0.14 to 0.16 mm/day; P < .001 vs bortezomib only; P = 0.03 vs vehicle).
    1 context sentence
    Summary · context
    Mice with human neuroblastoma or medulloblastoma tumor xenografts (9-13 animals/group) received one 2-week cycle (2 injections/week) of bortezomib (0.8 mg/kg or 1.0mg/kg), or HNG (1 µg/mouse), or the combination of HNG/bortezomib, or vehicle.

    In this study, Humanin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Humanin.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 21:44 UTC

    Study results updated

  2. Version 1

    13 Oct 2026, 16:31 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.